Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D. Colan

Showing results (241-250 of 290) with videos related to

Pageof 29
Sort By:
American Heart Journal|December 21, 2010
Clinical research careers: reports from a NHLBI pediatric heart network clinical research skills development conferenceWyman W Lai, Victoria L Vetter, Marc Richmond, et al.
Cardiology in the Young|February 12, 2011
Report from The International Society for Nomenclature of Paediatric and Congenital Heart Disease: cardiovascular catheterisation for congenital and paediatric cardiac disease (Part 1 - Procedural nomenclature)Lisa Bergersen, Allen Dale Everett, Jorge Manuel Giroud, et al.
Circulation. Heart Failure|September 14, 2010
Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood: an outcomes study from the Pediatric Cardiomyopathy RegistrySusan R Foerster, Charles E Canter, Amy Cinar, et al.
Open Heart|November 28, 2017
Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathyJennifer E Ho, Ling Shi, Sharlene M Day, et al.
American Heart Journal|September 26, 2007
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndromeRonald V Lacro, Harry C Dietz, Lisa M Wruck, et al.
JAMA Cardiology|February 28, 2017
The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet StudyCarolyn Y Ho, Sharlene M Day, Steven D Colan, et al.
Pediatrics|November 21, 2012
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac OutcomesSteven E Lipshultz, Tracie L Miller, Stuart R Lipsitz, et al.
Cardiology in the Young|November 21, 2022
A novel algorithm for classification of interatrial communications within the oval fossa in the newbornSofie Dannesbo, Elisabeth Blixenkrone-Moeller, Christian A Pihl, et al.
The Lancet. Oncology|September 21, 2010
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trialSteven E Lipshultz, Rebecca E Scully, Stuart R Lipsitz, et al.
Circulation|October 10, 2018
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)Carolyn Y Ho, Sharlene M Day, Euan A Ashley, et al.
Pageof 29

Showing results (241-250 of 290) with videos related to

Sort By:
Pageof 29
American Heart Journal|December 21, 2010
Clinical research careers: reports from a NHLBI pediatric heart network clinical research skills development conferenceWyman W Lai, Victoria L Vetter, Marc Richmond, et al.
Cardiology in the Young|February 12, 2011
Report from The International Society for Nomenclature of Paediatric and Congenital Heart Disease: cardiovascular catheterisation for congenital and paediatric cardiac disease (Part 1 - Procedural nomenclature)Lisa Bergersen, Allen Dale Everett, Jorge Manuel Giroud, et al.
Circulation. Heart Failure|September 14, 2010
Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood: an outcomes study from the Pediatric Cardiomyopathy RegistrySusan R Foerster, Charles E Canter, Amy Cinar, et al.
Open Heart|November 28, 2017
Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathyJennifer E Ho, Ling Shi, Sharlene M Day, et al.
American Heart Journal|September 26, 2007
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndromeRonald V Lacro, Harry C Dietz, Lisa M Wruck, et al.
JAMA Cardiology|February 28, 2017
The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet StudyCarolyn Y Ho, Sharlene M Day, Steven D Colan, et al.
Pediatrics|November 21, 2012
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac OutcomesSteven E Lipshultz, Tracie L Miller, Stuart R Lipsitz, et al.
Cardiology in the Young|November 21, 2022
A novel algorithm for classification of interatrial communications within the oval fossa in the newbornSofie Dannesbo, Elisabeth Blixenkrone-Moeller, Christian A Pihl, et al.
The Lancet. Oncology|September 21, 2010
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trialSteven E Lipshultz, Rebecca E Scully, Stuart R Lipsitz, et al.
Circulation|October 10, 2018
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)Carolyn Y Ho, Sharlene M Day, Euan A Ashley, et al.
Pageof 29